UNITED STATES

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): June 1, 2004

GENTA INCORPORATED

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

0-19635 (Commission File Number)

33-0326866

(IRS Employer Identification No.)

Two Connell Drive Berkeley Heights, NJ (Address of Principal Executive Offices)

07922

(Zip Code)

(908) 286-9800

(Registrant s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Edgar Filing: GENTA INC DE/ - Form 8-K

Item 5. Other Events and Regulation FD Disclosure.

On May 28, 2004, Genta Incorporated (Genta) issued a press release announcing the termination of Genasense Expanded Access Program in Melanoma. The press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

 Exhibit Number	Description
99.1	Press Release dated May 28, 2004

Edgar Filing: GENTA INC DE/ - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

GENTA INCORPORATED

Date: June 1, 2004 By: /s/ William P. Keane

Name: William P. Keane

Title: Vice President, Chief Financial

Officer and Corporate Secretary

Edgar Filing: GENTA INC DE/ - Form 8-K

EXHIBIT INDEX

Exhibit Number	Description	Sequentially Numbered Page
99.1	Press Release dated May 28, 2004	